Analysts Set 2seventy bio, Inc. (NASDAQ:TSVT) Target Price at $7.20

2seventy bio, Inc. (NASDAQ:TSVT) has been given a consensus rating of “Moderate Buy” by the six analysts that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $7.20.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of 2seventy bio in a research report on Saturday, February 1st.

Hedge Funds Weigh In On 2seventy bio

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Erste Asset Management GmbH acquired a new stake in shares of 2seventy bio during the third quarter worth $25,000. Northern Trust Corp grew its holdings in shares of 2seventy bio by 1.4% during the fourth quarter. Northern Trust Corp now owns 408,083 shares of the company’s stock worth $1,200,000 after purchasing an additional 5,470 shares during the last quarter. Eversept Partners LP grew its holdings in shares of 2seventy bio by 0.6% during the fourth quarter. Eversept Partners LP now owns 1,003,678 shares of the company’s stock worth $2,951,000 after purchasing an additional 5,599 shares during the last quarter. American Century Companies Inc. grew its holdings in shares of 2seventy bio by 6.6% during the fourth quarter. American Century Companies Inc. now owns 93,552 shares of the company’s stock worth $275,000 after purchasing an additional 5,785 shares during the last quarter. Finally, Intech Investment Management LLC boosted its holdings in 2seventy bio by 41.1% in the fourth quarter. Intech Investment Management LLC now owns 20,688 shares of the company’s stock valued at $61,000 after acquiring an additional 6,030 shares during the last quarter. 93.90% of the stock is owned by institutional investors.

2seventy bio Price Performance

Shares of TSVT opened at $2.54 on Thursday. 2seventy bio has a 1-year low of $2.29 and a 1-year high of $6.40. The firm has a fifty day moving average price of $2.80 and a 200 day moving average price of $3.89. The stock has a market cap of $131.04 million, a PE ratio of -1.37 and a beta of 1.74.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.